(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 6.56% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Amneal Pharmaceuticals's revenue in 2026 is $3,045,859,000.On average, 8 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,007,473,977,136, with the lowest AMRX revenue forecast at $959,939,581,128, and the highest AMRX revenue forecast at $1,043,523,552,632. On average, 8 Wall Street analysts forecast AMRX's revenue for 2027 to be $1,094,886,222,144, with the lowest AMRX revenue forecast at $1,026,296,321,864, and the highest AMRX revenue forecast at $1,152,629,347,496.
In 2028, AMRX is forecast to generate $1,174,322,897,352 in revenue, with the lowest revenue forecast at $1,058,198,601,064 and the highest revenue forecast at $1,251,207,390,224.